Brai̇n drug targeti̇ng Beyne i̇laç hedeflendi̇ri̇lmesi̇

Çetin M., ÇAPAN Y.

Ankara Universitesi Eczacilik Fakultesi Dergisi, vol.33, no.4, pp.287-305, 2004 (Scopus) identifier

  • Publication Type: Article / Review
  • Volume: 33 Issue: 4
  • Publication Date: 2004
  • Journal Name: Ankara Universitesi Eczacilik Fakultesi Dergisi
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.287-305
  • Keywords: Blood-brain barrier (BBB), Brain, Central nervous system (CNS), Chimeric peptide technology
  • Lokman Hekim University Affiliated: No


The transport of compounds from the circulating blood into the central nervous system (CNS) is restricted by the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier. Owing to the presence of the the blood-brain barrier (BBB), more than 98% of all potential new drugs discovered for CNS do not cross the BBB. This barrier is formed by special endothelial cells sealed with tight junctions. It protects the nervous system against changes in the environment. Only a small class of drugs such as small molecules with unionized, lipophilic and low molecular weight molecules (< 400-500 Da) cross the BBB. However, polar and lipid-insoluble substances such as amino acids, peptides, proteins, and neuropeptides need specific carrier systems (liposomes, nanoparticles, and chimeric peptide technology etc.) to pass into the brain.